{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:08:48Z","timestamp":1779361728221,"version":"3.51.4"},"reference-count":5,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Bimekizumab shows high efficacy in moderate\u2010to\u2010severe hidradenitis suppurativa, achieving deep clinical responses and improving structural lesions such as draining tunnels. However, mucocutaneous candidiasis is the most characteristic adverse event due to IL\u201017 pathway inhibition, although it is usually mild and manageable. Based on clinical experience, a proactive, risk\u2010adapted approach including targeted antifungal strategies may improve tolerability. This perspective supports shifting from reactive to preventive management to optimize long\u2010term treatment persistence.<\/jats:p>","DOI":"10.1111\/ijd.70491","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:00:21Z","timestamp":1779361221000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted Prevention and Management of Mucocutaneous Candidiasis During Bimekizumab Therapy in Hidradenitis Suppurativa: A Practical Clinical Perspective"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2121-6727","authenticated-orcid":false,"given":"Francisco Javier","family":"Melgosa Ramos","sequence":"first","affiliation":[{"name":"Department of Dermatology University Hospital Llu\u00eds Alcany\u00eds  X\u00e0tiva Valencia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Mataix","sequence":"additional","affiliation":[{"name":"Department of Dermatology Marina Baixa Hospital  Alicante Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Santos Alarc\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Virgen de los Lirios  Alicante Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Mar\u00eda","family":"Ortiz Salvador","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital General Universitario  Valencia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Mart\u00edn Ezquerra","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital del Mar  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1378-1590","authenticated-orcid":false,"given":"Antonio","family":"Martorell","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital de Manises  Valencia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"10443","key":"e_1_2_5_2_1","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and Safety of Bimekizumab in Patients With Moderate\u2010To\u2010Severe Hidradenitis Suppurativa (BE HEARD I and BE HEARD II): Two 48\u2010Week, Randomised, Double\u2010Blind, Placebo\u2010Controlled, Multicentre Phase 3 Trials","volume":"403","author":"Kimball A. B.","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"e_1_2_5_3_1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/jdv.20472","article-title":"European S2k Guidelines for Hidradenitis Suppurativa\/Acne Inversa Part 2: Treatment","volume":"39","author":"Zouboulis C. C.","year":"2025","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"6","key":"e_1_2_5_4_1","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jaip.2023.04.015","article-title":"The Th17\/IL\u201017 Axis and Host Defense Against Fungal Infections","volume":"11","author":"Tangye S. G.","year":"2023","journal-title":"Journal of Allergy and Clinical Immunology. In Practice"},{"issue":"11","key":"e_1_2_5_5_1","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1007\/s13555-025-01521-z","article-title":"Long\u2010Term Effectiveness and Safety of Bimekizumab in Patients With Moderate to Severe Hidradenitis Suppurativa Under Real Clinical Practice Conditions: The Importance of Combined Treatment in Hurley III Patients and Potential Factors Associated With Complete Response","volume":"15","author":"Mansilla\u2010Polo M.","year":"2025","journal-title":"Dermatol. Ther. (Heidelb.)"},{"issue":"5","key":"e_1_2_5_6_1","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/bcp.13185","article-title":"First\u2010In\u2010Human Randomized Study of Bimekizumab, a Humanized Monoclonal Antibody and Selective Dual Inhibitor of IL\u201017A and IL\u201017F, in Mild Psoriasis","volume":"83","author":"Glatt S.","year":"2017","journal-title":"British Journal of Clinical Pharmacology"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.70491","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.70491","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.70491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:00:22Z","timestamp":1779361222000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.70491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":5,"alternative-id":["10.1111\/ijd.70491"],"URL":"https:\/\/doi.org\/10.1111\/ijd.70491","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"2026-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ijd.70491"}}